Search

Displaying results 2631 - 2640 of 10000 in total
  1. Drug

    Enasidenib

    go.drugbank.com/drugs/DB13874
    ApprovedInvestigational

    Food and Drug Administration on August 1, 2017. … Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2)

  2. Drug

    Normethadone

    go.drugbank.com/drugs/DB11609
    ApprovedIllicit

    Normethadone is used as an opioid antitussive in combination with [DB11610]. It is marketed in Canada by Valeant under the tradename Cophylac.

  3. Drug

    rdESAT-6

    go.drugbank.com/drugs/DB21906
    Approved

    rdESAT-6 is a recombinant dimer of _Mycobacterium tuberculosis_ early secretory antigenic target used as an ingredient in the diagnostic agent SIILTIBCY along with [rCFP-10].[L53638]

  4. Drug

    Rivastigmine

    go.drugbank.com/drugs/DB00989
    ApprovedInvestigational

    Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

    Categories: Compounds used in a research, industrial, or household settingProducts: RIVASTIGMIN ZEN 13.3MG/24H
  5. Drug

    Bopindolol

    go.drugbank.com/drugs/DB08807
    Experimental

    Bopindolol (INN) is an ester prodrug for the beta blocker [pindolol].

  6. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    an IgG2 framework. … [eculizumab] in June 2019 and [inebilizumab] in June 2020).

    Products: ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML, ENSPRYNG 120 mg/1ml solution for injection in pre-filled syringe
  7. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955] … It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation.

  8. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    [L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for

  9. Drug

    Protriptyline

    go.drugbank.com/drugs/DB00344
    Approved

    The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. … They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation.

    Synonyms: 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine, N-methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine
  10. Drug

    Clobazam

    go.drugbank.com/drugs/DB00349
    ApprovedIllicitInvestigational

    Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. … [A256968,A256973] Clobazam has been marketed as an anxiolytic since 1975 and an anticonvulsant since 1984.